The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.

Name: Αlpha¹ Rigor Record — The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.
Item: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.
Rating: 59
Author: Αlpha¹

Wu J, Pei F, Zhou L, Li W, Sun R, Li Y, Wang Z, He Z, Zhang X, Jin X, Long Y, Cui W, Wang C, Chen E, Zeng J, Yan J, Lin Q, Zhou F, Huang L, Shang Y, Duan M, Zheng W, Zhu D, Kou Q, Zhang S, Liu Y, Yao C, Shang M, Peng S, Zhou Q, Cheng KK, Guan X, TESTS study collaborator group

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.25★ (Weak), 0 critical, 0 high issues for “The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsStatistic did not reproduce ×2−1★
IntegrityIntegrity concern ×2−1★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×5−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies3

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted, rigorously reported phase 3 RCT with strong methodology, clear ethics approvals, and transparent data sharing. Minor reporting gaps include the absence of an explicit CONSORT statement and some copyedit inconsistencies, but these do not undermine the scientific integrity.

All three reviewers classified the study as interventional, which is consistent with the RCT design. The statistics verification component covered only a subset of tests; the 7 inconsistent tests were not specified and may reflect rounding or unverifiable threshold-only p-values, so they were not treated as errors. The citation check found no retracted or non-existent references.

6 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 1 via agent-written checks. 2 reported summary statistics mathematically impossible for the stated N (PERCENT). 5 printed percentages that do not match their own count.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior small studies and a meta-analysis showing potential benefit, acknowledges their limitations (small sample sizes, low quality), and provides a logical rationale for the trial. The limitations of prior research are explicitly discussed, including lack of masking and imbalance in key characteristics.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 70% conf

The premise is well-established with prior literature and a meta-analysis, but the cited meta-analysis (10 RCTs, 530 patients) is small and of low quality, and the authors acknowledge this limitation.

Evidence

paraphrase[Introduction, paragraph 3]

“A meta-analysis of 10 randomised controlled trials with a total of 530 patients suggested that thymosin α1 might offer a 41% relative reduction in 28 day mortality (22% v 38%, relative risk 0.59, 95% confidence interval 0.45 to 0.77), but the quality of evidence was low owing to the small sample sizes of the included trials.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

direct quote[Introduction, paragraph 2]

“A meta-analysis of 10 randomised controlled trials with a total of 530 patients suggested that thymosin α1 might offer a 41% relative reduction in 28 day mortality (22% v 38%, relative risk 0.59, 95% confidence interval (CI) 0.45 to 0.77), but the quality of evidence was low owing to the small sample sizes of the included trials.”